Please login to the form below

Not currently logged in

Eurocine Vaccines appoints chief scientific officer and chief business officer

Anna-Karin Maltais and Emma Berglund both receive promotions

Eurocine Vaccines has appointed Dr Anna-Karin Maltais as chief scientific officer and promoted business development manager Emma Berglund to chief business officer.

Dr Maltais, who also becomes head of R&D, takes over from Professor Jorma Hinkula, who has returned to his previous position as professor at the University of Linköping in Sweden.

In her new role, Dr Maltais will oversee Eurocine's vaccines development programme, which includes Immunose – a nasal vaccine for influenza.

“Dr Maltais has extensive experience in vaccine development from both academia and industry,” said the company's CEO Hans Arwidsson.

“Her expertise in vaccine delivery and adjuvants is extremely valuable to the company and with her industry background we can run our projects with an even stronger commercial focus.”

This includes several years at Cyto Pulse Sciences, where she served as manager EU operations and then VP, corporate development.

Berglund had been in her previous position since 2009, and has prior business development experience at both Biovitrum and Avaris.

25th September 2012

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...